VAERS reports by lot

GSK DTaP/Tdap lot XG942: VAERS reports

27 VAERS reports list lot XG942 as a GSK DTaP/Tdap vaccine, received between 2021-01-29 and 2023-10-02. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
27
Reports
4%
Marked serious
0
With a death outcome
17
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Injection-site / Local reaction725%
Dermatological (non-injection-site)518%
Neurological311%
Gastrointestinal311%
General / Systemic (non-local)311%
Cardiac / Cardiovascular27%
Musculoskeletal27%
Allergic / Anaphylactic14%
Respiratory14%
Psychiatric / Neuropsychiatric14%

Where reports came from

U.S. state of the reporter, where given (top 12).

Pennsylvania3
Arizona2
Michigan2
South Carolina2
Massachusetts2
New Hampshire2
New York1
Nebraska1
Georgia1
Kansas1
California1
Texas1

Reports by month received

2021-011
2021-022
2021-032
2021-041
2021-051
2021-072
2021-082
2021-091
2021-101
2022-031
2022-042
2022-063
2022-094
2022-101
2022-111
2023-021
2023-101

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.